A highly regarded patent attorney, Michael specialises in the field of biotechnology and has particular expertise in the drafting and prosecution of patent applications concerning immunotherapy, protein stability, biologics, therapeutic strategies, gene therapy, metabolic profiling, drug delivery, and assay technologies.
In addition to acting before the European Patent Office both in prosecution and opposition matters, he has also devised global patent filing strategies and has managed the prosecution of several global patent portfolios, including applications in Australia, Canada, China, India, Japan and the US. His clients range from technology/knowledge transfer and start-ups/spinouts through to multinational corporations, covering early-stage research as well as more developed products.
Michael has extensive experience in the niche area of supplementary protection certificates (SPCs), a form of IP that can provide an additional monopoly period beyond patent expiry for some medicinal and plant protection products. As well as authoring various articles on the topic and speaking at international conferences, Michael has been involved in coordinating the prosecution of high profile SPC portfolios throughout Europe, including a case that was referred to the Court of Justice of the European Union.
Michael joined Potter Clarkson in 2006 and qualified as a Chartered Patent Attorney and European Patent Attorney in 2010.
Year Joined Firm: 2006
Education/Alumni: Michael read natural sciences (biochemistry) at Cambridge University before obtaining a PhD in biochemistry at the same university, where Merck Sharp Dohme sponsored his research. His research involved using metabolic profiling techniques to study a childhood neurodegenerative disease. During his PhD, he authored several papers in the field of functional genomics.
